insights_auto
Why is CORT up 2.24%?
Dive Deeperchevron_right
CORT:NASDAQ
Corcept Therapeutics Inc
$121.19
arrow_upward
+2.24%(+2.65) 1D
$121.19
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CORT...
Open
$118.00
High
$122.34
Low
$117.41
Mkt. cap
13.10B
Avg. vol.
1.44M
Volume
624.21K
P/E ratio
284.45
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.40
Shares outstanding
108.10M
No. of employees
730
Open
$118.00
High
$122.34
Low
$117.41
Mkt. cap
13.10B
Avg. vol.
1.44M
Volume
624.21K
P/E ratio
284.45
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.40
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 week ago
CORT Q2 2026 Earnings: Earnings Per Share of $0.36 Smashes a Near-Zero Consensus Estimate - CEO Earnings Statement
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com